145 related articles for article (PubMed ID: 1732425)
1. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.
Markman M; Hakes T; Reichman B; Lewis JL; Rubin S; Jones W; Almadrones L; Pizzuto F; Hoskins W
J Clin Oncol; 1992 Feb; 10(2):243-8. PubMed ID: 1732425
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide and mesna in epithelial ovarian carcinoma.
Sutton G
Gynecol Oncol; 1993 Oct; 51(1):104-8. PubMed ID: 8244163
[TBL] [Abstract][Full Text] [Related]
3. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
Sutton GP; Blessing JA; Homesley HD; Berman ML; Malfetano J
J Clin Oncol; 1989 Nov; 7(11):1672-6. PubMed ID: 2509641
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Schryber S; Hunt M; Critchlow J; Schnipper L
J Clin Oncol; 1991 Feb; 9(2):320-7. PubMed ID: 1846407
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen.
González-Martín A; Crespo C; García-López JL; Pedraza M; Garrido P; Lastra E; Moyano A
Gynecol Oncol; 2002 Mar; 84(3):368-73. PubMed ID: 11855871
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
Markman M; Kennedy A; Sutton G; Hurteau J; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 1998 Aug; 70(2):272-4. PubMed ID: 9740704
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy.
Sørensen P; Pfeiffer P; Bertelsen K
Gynecol Oncol; 1995 Jan; 56(1):75-8. PubMed ID: 7821851
[TBL] [Abstract][Full Text] [Related]
9. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
Polyzos A; Tsavaris N; Kosmas C; Petrikos G; Giannikos L; Kalahanis N; Papadopoulos O; Christodoulou K; Giannakopoulos K; Veslemes M; Katsilambros N
J Chemother; 1999 Apr; 11(2):144-9. PubMed ID: 10326746
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Antman KH; Elias A; Ryan L
Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
[TBL] [Abstract][Full Text] [Related]
12. High-dose ifosfamide with mesna uroprotection: a phase I study.
Elias AD; Eder JP; Shea T; Begg CB; Frei E; Antman KH
J Clin Oncol; 1990 Jan; 8(1):170-8. PubMed ID: 2104923
[TBL] [Abstract][Full Text] [Related]
13. Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Cancer Chemother Pharmacol; 1990; 26 Suppl():S55-8. PubMed ID: 2112054
[TBL] [Abstract][Full Text] [Related]
14. Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer.
Chiara S; Tognoni A; Pastrone I; Tomasello L; Brema F; Di Costanzo G; Folco U; Pronzato P;
Gynecol Oncol; 2004 May; 93(2):474-8. PubMed ID: 15099965
[TBL] [Abstract][Full Text] [Related]
15. Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study.
Toma S; Palumbo R; Comandone A; Oliva C; Vincenti M; Bumma C; Rosso R
Ann Oncol; 1995 Feb; 6(2):193-6. PubMed ID: 7540421
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
Sutton GP; Blessing JA; Homesley HD; McGuire WP; Adcock L
Cancer; 1994 Mar; 73(5):1453-5. PubMed ID: 8111713
[TBL] [Abstract][Full Text] [Related]
17. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
[TBL] [Abstract][Full Text] [Related]
18. A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy.
Scarfone G; Villa A; Parazzini F; Sciatta C; Polverino G; Bolis G
Tumori; 1999; 85(4):217-9. PubMed ID: 10587020
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study.
Sutton GP; Blessing JA; Homesley HD; Malfetano JH
Gynecol Oncol; 1994 Apr; 53(1):24-6. PubMed ID: 8175017
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas.
Ajani JA; Abbruzzese JL; Goudeau P; Faintuch JS; Yeomans AC; Boman BM; Nicaise C; Levin B
J Clin Oncol; 1988 Nov; 6(11):1703-7. PubMed ID: 3141592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
